15 Best Retirement Stocks to Buy According to the Media

In This Article:

In this article, we discuss the 15 best retirement stocks to buy according to the media. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Retirement Stocks to Buy According to the Media

There is increased investor interest in the American stock market as growth metrics make headlines after a macro slowdown in the past two years. Investors have been given confidence as prospects of lowered rates serve to boost the major indexes to swing upwards. For example, the S&P 500 is up more than 8% in the past two months, the NASDAQ Composite is up close to 9%, and the Dow Jones has registered gains of around 3%. This is quite extraordinary given the contraction of the indexes in the past few months as rates went up. 

There are several other reasons for investors to be optimistic about the health of the US stock market. Inflation figures have started showing signs of slowing down, consumer spending is holding steady, the labor market remains resilient as ever, and financial experts have come together to predict that the US will be able to avoid a major recession. As the market normalizes, big companies like Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), and The Proctor and Gamble Company (NYSE:PG) are all performing exceptionally well. 

These firms have been able to withstand inflationary pressures and emerge stronger than ever from the crisis of the past two years. Generally, the three firms mentioned above are considered safe stocks for a retirement portfolio since they have established businesses, a solid track record of dividend payouts, and a steady growth profile. Joaquin Duato, the CEO of Johnson & Johnson (NYSE:JNJ), recently gave an insight into the future plans of his company, at the fourth quarter earnings call, that might be of interest to investors.

“As we look ahead, I have never been more excited about the future of our business. At our enterprise business review, we shared that we expect our innovative medicine business to grow 5% to 7% from 2025 to 2030 with our industry-leading pipeline and portfolio delivering more than 10 assets that have the potential to generate over $5 billion in peak year sales by 2030. We also expect a further 15 assets to have the potential for $1 billion to $5 billion in peak year sales. In 2024, we expect data readouts for many of these assets, including Phase 3 trials for Tremfya in IBD; Erleada in early stage prostate cancer; our targeted oral peptide, JNJ-2113 in psoriasis; nipocalimab in myasthenia gravis; as well as aticaprant and seltorexant in major depressive disorder.